• Genmab maintained 2026 revenue guidance of USD 4.33 billion–USD 4.53 billion, implying 19% growth at the midpoint.
• Adjusted operating profit is forecast at USD 1.07 billion–USD 1.39 billion, with adjusted operating expenses of USD 2.81 billion–USD 2.95 billion.
• Spending targets accelerated late-stage development of petosemtamab and Rina-S, alongside launch preparations.
• EPKINLY sales and continued royalty portfolio momentum support the revenue outlook.
• Nine-month revenue rose 22% to USD 3.24 billion; adjusted operating profit increased 9% to USD 1.11 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genmab A/S published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.